Cellebrite DI Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of August 2026 for Cellebrite DI Ltd., a foreign private issuer. The filing primarily addresses a significant change in executive leadership and board composition effective August 13, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of corporate governance changes and does not contain financial performance data.
Material Changes
- CEO Transition: Thomas E. Hogan ceased serving as Chief Executive Officer effective August 13, 2026, pursuant to a mutual agreement.
- Succession: Shiven Ramji was appointed as the new Chief Executive Officer as part of a planned succession.
- Board Resignation: Thomas E. Hogan resigned from the board of directors effective August 13, 2026.
- Advisory Role: Mr. Hogan agreed to serve as an advisor to the Company for a period of six months following his departure.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, outlook, or management commentary regarding future performance. The primary risk disclosed relates to the transition of leadership, though it is characterized as a planned succession. The contents of this report are incorporated by reference into the Company's registration statements on Form S-8 and Form F-3.
Key Facts for Investor Verification
- Confirm the effective date of Shiven Ramji's appointment as CEO (August 13, 2026).
- Verify the terms of Thomas E. Hogan's six-month advisory agreement.
- Review subsequent filings for the impact of this leadership change on strategic direction.
- Note that no financial results are included in this specific 6-K filing.